May had failed to win a parliamentary majority on Britain's withdrawal from the European Union.Europe Politicsread more
Investors are rushing into the relative safe haven of the bond market, causing the yield on the U.S. 10-year Treasury to plummet.Real Estateread more
China denounced U.S. Secretary of State Mike Pompeo for fabricating rumors after he said the chief executive of China's Huawei was lying about his company's ties to the...World Politicsread more
U.S. President Donald Trump on Thursday predicted a swift end to the ongoing trade war with China, although no high-level talks have been scheduled between the two countries.World Economyread more
President Donald Trump has threatened tariffs on another $300 billion worth of Chinese goods — but Chinese PC-maker Lenovo is prepared to shift its production if that happens,...Technologyread more
Indian Prime Minister Narendra Modi won a landslide re-election victory. That could see India taking a more assertive security stance.Asia Politicsread more
The Wall Street Journal and The New York Times, citing people familiar with the deal, reported that $30 million would go to plaintiffs and $14 million would be used to pay...Entertainmentread more
Danish shipping group A.P. Moller-Maersk on Friday posted first-quarter profit close to expectations and warned that trade tensions and slowing economic growth constitute...Earningsread more
Chinese technology giant Huawei has enough inventory to sustain its smartphone and 5G networking equipment business for most of the rest of the year, according to brokerage...Technologyread more
President Donald Trump on Thursday directed the U.S. intelligence community to "quickly and fully cooperate" with Attorney General William Barr's investigation into the...Politicsread more
Despite a decline in global commercial real estate markets, Asia-Pacific continues to enjoy a record-breaking growth — thanks to China, according to the Global Capital Flows...Real Estateread more
The Food and Drug Administration accused a medical company of failing to investigate "hundreds of complaints that" the anti-allergy EpiPen device has misfired "during life-threatening emergencies," including some cases in which people later died.
The letter cites multiple "significant" regulatory violations related to the manufacturing of EpiPen discovered during inspections during February and March of this year at a Missouri facility operated by Meridian Medical Technologies, the Pfizer-owned company.
It is the same facility that produced EpiPen lots which were subject to a recall earlier this year after two reports of the auto-injector devices misfiring. At the end of that recall, which is mentioned in the FDA letter, there were no public reports of deaths associated with EpiPens.
EpiPens are used to deliver a dose of the drug epinephrine to people who are suffering a potentially fatal allergic reaction known as anaphylaxis.
Mylan is the leading seller, by far, of auto-injectors containing epinephrine.
The FDA's letter dated Tuesday to Meridian noted that "patients can died or suffer serious illness" if the EpiPen injectors do not operate as expected, or do not deliver the intended dose of epinephrine.
Despite that, the FDA charged, "you failed to thoroughly investigate multiple serious component and product failures for your EpiPen products, including failures associated with patient deaths and severe illness."
"Your own data show that you received hundreds of complaints that your EpiPen products failed to operate during life-threatening emergencies, including some situations in which patients subsequently died," the letter said.
Many of those complaints involved failures of EpiPen to activate when a user followed instructions for the device, the FDA said.
There were also complaints that the EpiPens had "spontaneously dispensed epinephrine drug prior to use so that the drug was no longer available when the user attempted to activate the product," according to the letter.
Between 2014 and 2017, Meridian records show, the company received samples of 171 EpiPens related to complaints that they failed to activate when a patient followed instructions properly.
The FDA noted that Meridian disassembled only a fraction of those 171 samples, and that when asked why that was the case, a quality control official at the company told inspectors it was policy not to disassemble the product unless "approved by management."
"Not only did Meridian not thoroughly investigate the complaints about EpiPens, the FDA said, but the company also did not remove "potentially defective products from the marketplace" despite the fact that "you had identified a a defect in one of the critical components use to manufacture these products."
The FDA ordered Pfizer's unit to correct the violations promptly. The agency's letter also says failure to do so may result in legal action including seizure and injunction.
When asked for comment, a Pfizer spokeswoman told CNBC, "Between 2015 and now, we have shipped more than 30 million EpiPen Auto-Injectors globally. It's not unusual to receive product complaints, especially when the product is frequently administered by non-medically trained individuals. We currently have no information to indicate that there was any causal connection between these product complaints and any patient deaths.
"We are very confident in the safety and efficacy of EpiPen products being produced at the site," the Pfizer spokeswoman said.
A spokeswoman for Mylan said, "Pfizer is continuing to work with FDA to resolve the points raised in the letter regarding Pfizer's manufacturing of EpiPen Auto-Injector and Mylan will do whatever it can to support this process."
"We note that Pfizer's recall several months ago of certain lots of EpiPen Auto-Injector was taken as a proactive and precautionary measure with FDA in relation to these issues," the Mylan spokeswoman said.
"Mylan has an unwavering commitment to quality and patient safety and we are confident in the safety and efficacy of EpiPen products being produced at the site. Further, we do not currently anticipate any supply issues as a result of the warning letter."